glp 1 alzheimer's study Popular obesity drug fails in hotly anticipated trials | Science Details of failed studies cast

2017;9:eaan0972

British J

J Cell Physiol 1997

The program is designed to help eligible Medicare Part D beneficiaries access certain GLP-1 medications when they are prescribed for weight loss, obesity treatment, or maintaining weight reduction

Buy dilemma

McGraw-Hill / Lange rxlist.com (Amaryl ) rxlist.com (Glucotrol ) rxlist.com (DiaBeta ) Keywords Glinides Repaglinide Trade Name: Prandin Drug Class: oral hypoglycemic, insulin secretagogue, meglitinide, glinide Mechanism of Action: Similar to sulfonylureas - inhibits potassium efflux (blocks ATP-regulated K channels), causing depolarization & insulin release from pancreatic -cells (see Figure 1 in Beta Cell Pharmacology) has a weaker binding affinity and faster dissociation from the SUR1 binding site compared to sulfonylureas Stimulates a transient release of insulin from pancreatic beta cells that, when administered with a meal, is useful for controlling postprandial hyperglycemia associated with Type 2 diabetes (see Figure 2 in Beta Cell Pharmacology)